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1.0 ABSTRACT:   
Biomarkers can be used to establish more homogeneous groups using the genetic makeup of 
the tumour to inform the selection of treatment for each individual patient.  However, proper 
preclinical work and stringent validation are needed before taking forward biomarkers into 
confirmatory studies.  Despite the challenges, incorporation of biomarkers into clinical trials 
could better target appropriate patients, and potentially be lifesaving.  The authors conducted 
a systematic review to describe marker-based and adaptive design methodology for their 
integration in clinical trials, and to further describe the associated practical challenges. 
Studies published between 1990 to November 2015 were searched on PubMed.  Titles, 
abstracts and full text articles were reviewed to identify relevant studies. Of the 4438 studies 
examined, 57 studies were included. The authors conclude that the proposed approaches may 
readily help researchers to design biomarker trials, but novel approaches are still needed. 
 
2.0 INTRODUCTION: 
Considerable challenges exist in the incorporation of biomarkers into clinical trials. 
This explains why they are mostly included as exploratory endpoints into current oncology 
clinical trials (1).  Individual patient heterogeneity, both between primary and sites of 
metastasis as well as within metastatic lesions, is a major concern for successful treatment of 
advanced tumours (2).  As patient biopsies often target a single piece of tissue at one time 
point only, and not at multiple ones longitudinally, tumour heterogeneity and alterations over 
time are not properly addressed, although they likely contribute to the evolution of drug 
resistance (2).  Furthermore, biomarkers can represent molecular aberrations that can be 
driver or passenger events (2).  Other issues include the percentage of cells and the method of 
obtaining a tumour sample, and in what sequence multi-combinatorial agents as well as their 
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dose levels should be used to target multiple aberrations (2). Despite this, biomarkers can be 
used to establish more homogeneous groups using the genetic makeup of the tumour to 
inform the selection of treatment for individual patients (3).   
Biomarkers are classified into a few categories in the literature: prognostic, predictive, 
surrogate, screening or diagnostic, pharmacodynamic efficacy and resistance, and integral 
and integrated biomarkers (4-6).  For the purposes of this article, we mainly focus on 
prognostic and predictive markers; with a brief overview of the others. A surrogate marker is 
a biomarker accepted by regulatory agencies as a substitute for a clinical endpoint and, when 
used as an early indicator of treatment efficacy,  is potentially attractive in terms of cost-
effectiveness (4); e.g. HIV load.  Screening or diagnostic markers are used in the monitoring 
of disease including PSA levels in prostate cancer. Pharmacodynamic efficacy and resistance 
biomarkers are used to measure response and resistance to treatment, respectively (5). 
Finally,  integral biomarkers determine patient incorporation and/or directs clinical trial 
procedures, while integrated biomarkers are not used to determine patient treatment (6).  
Prognostic markers provide an early indication of the clinical course of a patient independent 
of any specific intervention and may be considered in the clinical management of a patient; 
e.g. BRCA1/2 mutation-which can also be predictive of PARP inhibitors.  These are 
prevalent in the literature, and guidelines for their evaluation are available with the gold 
standard being the REMARK criteria (7, 8).  Predictive biomarkers are measured prior to an 
intervention and identify patients who are susceptible to a particular drug effect; however 
they are not necessarily prognostic of post-treatment clinical course (3),  e.g. HER2 or  
KRAS (9).  Predictive markers can only be properly validated in a prospectively designed 
randomized controlled trial testing for a marker-by-treatment interaction (10); but a very 
large sample size is often required (11).  A biomarker can be both prognostic and predictive 
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such as Estrogen Receptor status and its prognostic association with relapse and its 
predictiveness of treatment benefit from tamoxifen (12). 
It is critical that proper preclinical work and stringent validation be done before taking 
forward only the most promising biomarkers into confirmatory studies.  The aim of this 
article is to provide an overview on the methods to incorporate biomarkers into clinical trials 
and to further describe the challenges.   
 
3.0 MATERIALS AND METHODS: 
 Study selection followed the process described in the diagram in Figure 1.  The design 
name, whether they are marker-based, adaptive, used in design in or testing during a trial, 
their description, advantages and disadvantages and trials using those designs were retrieved.   
 
4.0 RESULTS: 
Figure 1: 
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Fifty-seven articles were included in the review, and methods of incorporating biomarkers 
were identified (Table 1). Broadly, the methods fall into marker-based or adaptive, and being 
used as design or testing methods; and other novel designs. 
4.1. Overview of marker-based methods: 
One of the most commonly used marker-based designs is the enrichment or targeted 
design (Figure 2a), which is appropriate when there is compelling preliminary evidence to 
suggest that treatment benefit or lack of toxicity is restricted to patients with a certain 
biomarker profile (13).   An ideal biomarker for this design would need a well-established 
cut-off point and have an assay with a rapid turnaround time (4).  A successful enrichment 
design is very efficient, increases the power of a study as compared to the unselected/all 
comers design, and may require only a small sample size if the treatment effect is large in the 
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biomarker positive subgroup, even if the biomarker positivity prevalence is low in the 
population of interest (14).  Conversely, if the assay is imperfect, the treatment may actually 
have an effect in the negative subgroup or whole population which will remain unknown as 
only the positive subgroup is recruited (15, 16).  Furthermore, this design may require a large 
population to be screened to identify the biomarker positive subgroup; moreover, it cannot 
determine whether the biomarker is predictive or not.  A slight modification to the 
enrichment design is the hybrid or mixture design (Figure 2b) allowing the treatment effect of 
the intervention therapy in the biomarker positive subgroup to be compared with the 
treatment effect of the control arm in both the biomarker positive and negative population 
(16);  this design would still require a well-established biomarker. 
The vast majority of currently conducted trials collecting biological specimens for 
marker measurements use the Unselected or All Comers design (Figure 2c) as all patients 
meeting the eligibility criteria are entered into the trial independent of previous testing or the 
resulting status of the biomarker of interest.  Furthermore, one does not need to be certain 
about the benefit of the marker in either the overall population or the biomarker defined 
subgroups as it provides the treatment effect in the overall population as a whole (13).  Less 
established biomarkers needing further validation of their performance or having a slower 
assay turnaround times could be used in this design (4).  However, the cost of measuring the 
biomarker in the whole population will be large if a high proportion of patients are not able to 
contribute biomarker measurements, hence the prevalence of the biomarker should be high 
(16).   
The Marker-Based Strategy Design recruits eligible subjects regardless of their 
biomarker status, just like all-comer design and then randomly assigns the patients to either to 
have therapy determined by their marker status, in the biomarker directed arm, or to receive 
therapy independent of marker status  (14) (Figure 2d). This is a cost-effective design in 
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comparison to the enrichment or biomarker stratified design in that the biomarker is only 
assessed in the biomarker directed arm and it is ethical in that there are no issues, including 
compliance, associated with withholding the biomarker status from the control-arm patients 
(14).  As such this design can be used when multiple treatments are under investigation or 
when a treatment decision will be based on multiple markers (11);  much like the enrichment 
design, biomarkers should also be well established.  A major disadvantage with this design is 
the loss of power through the overlap in patients receiving the same treatment regimen in the 
biomarker directed and the control arm, as the biomarker is not assessed in the control arm 
(14). As randomisation has taken place before biomarker testing, the sub-populations may be 
imbalanced (11). As the intervention may be better than the control treatment for all patients 
regardless of biomarker status, a positive trial does not prove the utility of the biomarker (14).   
A modification to this design allows some clarification in whether any positive results are due 
to a true effect of marker status or to an improved regimen regardless of marker status (Figure 
2e) (14).    
The Interaction or Biomarker stratified design (Figure 2f) allows for the prognostic 
value of marker to be evaluated by comparing the outcomes of patients treated with the same 
regimen between the two marker groups (14).  Stratifying on the biomarker upfront assures 
that only patients with adequate test results will enter the trial (11). This design is inefficient 
as the trial needs to be powered to detect either a difference in the effect of the treatment in 
biomarker-positive and-negative patients through an interaction, which requires a very large 
number of patients, or the effect in all patients, which is likely to be small due to a potentially 
small or even negative effect in biomarker-negative patients (14).  This design also allows a 
test of interaction to be performed to determine whether a differential treatment effect exists 
in the two marker groups, assuming that the sample size is adequate for this test to be 
appropriately powered (11); it may not provide power for testing the treatment effect 
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separately in the two marker subgroups based on sample size (11).  However, if the primary 
question requires separate testing in the marker subgroups, the study would need to be 
powered on this basis.  Furthermore, this design cannot be used when multiple biomarkers or 
treatments are being evaluated due to cost as it is intended to evaluate one treatment or 
biomarker (11).  If the biomarker or treatment is ineffective, this design can further be quite 
wasteful (11).  An ideal biomarker for this design would not need to be as well-established in 
that equipoise would need to be present to justify randomly assigning these patients to 
therapy based on their biomarker status (14).  
Standard superiority and futility interim monitoring can be used for  most marker-based 
strategy and enrichment designs which simply focus on comparing the overall efficacy 
between the randomized arms (17); however these may be more difficult to use for 
biomarker-stratified designs due to the multiple hypotheses under study.  To help clarify 
which design to use for further phase III testing of an intervention, Freidlin et al proposed a 
randomised phase II trial design whose results could help investigators decide whether or not 
to stop testing of that particular intervention, or to use a biomarker enrichment, biomarker 
stratified or standard phase III design (18) for the future phase III trial. 
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Several statistical testing strategies can be used in the aforementioned designs if the required 
sample size to perform a subgroup-specific approach is not feasible. One such strategy is 
sequential testing which assumes that the new treatment is unlikely to be effective in the 
biomarker-negative patients unless it is effective in the biomarker positive patients (16, 19).  
This may make it difficult to determine whether the treatment is beneficial in the biomarker 
negative subgroup, as a large treatment effect in the biomarker positive patients could be 
driving an effect found in the whole population even if there is no treatment effect in the 
negative subgroup (19).  The Marker sequential test design helps avoid the conclusion that 
the treatment benefits all patients when the overall effect is driven by the biomarker-positive 
patients and recommends treatment to either the whole population or to no patients regardless 
of biomarker status depending on testing results (19, 20). The goal of this testing is to stop 
subgroups for which the hypothesis has been answered, and allow reallocation of resources to 
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the open subgroups (20, 21). In general, crossing the efficacy boundary in the biomarker-
positive subgroup results in stopping that subgroup, and crossing the inefficacy boundary 
results in the stopping of the entire study; however for the biomarker-negative subgroup, 
crossing either boundary results in the stopping of that subgroup only (20, 21).   
Other marker-based methods are described in Table 1.   
4.2. Overview of adaptive methods: 
 Adaptive designs are increasingly being used to incorporate biomarkers into clinical 
trials as they allow investigators to analyse the data mid-trial, associate those results with 
known biomarkers, and then modify the ongoing trial following the results, targeting those 
people most likely to benefit from their biomarker status (22, 23).  Advantages and 
disadvantages of adaptive designs have been covered extensively in the literature (16, 24, 25). 
Ideal biomarkers for adaptive designs usually have a well-established cut-off point and have 
an assay with a rapid turnaround time (4) but there is some uncertainty about the benefit in 
overall population versus marker defined subgroups.  
Bayesian adaptive randomization designs have been used to randomly assign patients 
to treatments based on the biomarker status.  While equal randomisation can improve the 
efficiency of a trial by maximizing the statistical power, adaptive randomization offers a 
higher probability of assigning more patients to a more efficacious treatment, especially when 
the treatment difference is large or the relevant disease is rare (24).  Several types of adaptive 
randomisation techniques have been proposed, including using short-term response 
information to facilitate adaptive randomization for survival clinical trials (26), covariate-
adaptive randomization (24),  response-adaptive randomization (24, 27) and outcome-based 
adaptive randomization (21, 28); however there may be potential bias if there are any time 
trends in the prognostic mix of the patients accruing to the trial (28).   Patient accrual can be 
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modified using designs such as the adaptive accrual design (16), the biomarker-adaptive 
parallel Simon two-stage design (29) and the phase III design for the setting of a single binary 
biomarker stratification design (15) (Table 1).  
 Adaptive versions of the aforementioned marker-based designs also have been 
proposed such as the Bayesian adaptive marker-stratified design (27), the adaptive 
enrichment design (30, 31) and an adaptive version of testing approaches using utility 
functions (32).  Furthermore, a Bayesian prediction model has been proposed to help predict 
whether a biomarker is truly associated to a clinical outcome using a meta-analytic approach 
(33).  Finally, a Bayesian adaptive design has been suggested for simultaneously testing 
several predictive biomarkers and new experimental treatments in multi-arm phase II trials 
(34) (Table 1).  
 Finding an appropriate cut-off point as well as the process of biomarker validation is 
very difficult.  Two adaptive designs have been proposed to help in this process.  The first is 
the biomarker-adaptive threshold design (35) (Figure 3a) where the optimal cut-off point 
identifying the subgroup of patients with the greatest treatment effect is determined in phase 
2 through a permutation analysis with confidence intervals further derived for the optimal 
threshold using bootstrap re-sampling (35).  The second is the adaptive signature design (36) 
(Figure 3b) where if the phase 1 analysis is not significant, phase 2 begins using the 
remaining α ; either half of the study population is used to develop a signature and the other 
half to validate it through comparison of outcomes for the sensitive patients in the 
intervention and control arm being compared (36), or practically the entire study population 
is used in both the signature development and the validation steps in a cross-validation 
extension of this design (37).  This approach was developed as the original method has 
limited power as only half of the patients are used in each of the development and validation 
portions of the design (36).  In the cross-validation method, the trial population is first split 
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into a validation and a development subpopulation (37).  For each development 
subpopulation, a predictive signature is developed which is then applied to find a subgroup of 
patients that are sensitive in the validation subpopulation (37).  The process is then repeated 
for all the validation subpopulations so that each patient in the trial population appears in 
exactly one of the validation subpopulations and that by the end of the procedure, each 
patient is classified as being sensitive or not (37). A test statistic is used to assess the presence 
of a treatment effect in the sensitive patient subgroup with a permutation method to obtain a 
corresponding P value (37). A permuted data set is constructed and the entire process is 
repeated for the permuted data set with the corresponding test statistic calculated each time 
(37).
 
 
Table 1:
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Name Description Key Advantages Key Disadvantages 
Trial example, if 
available (N/A=not 
available) 
Reference 
Number 
Marker-based design methods 
Enrichment/Targeted Figure 2a 
Efficient, Increases Power, 
Smaller sample size can be 
used when large treatment 
effect exists in biomarker 
positive subgroup 
Unknown effect whole 
population or marker negative 
subgroup, large population 
needs to be screened to 
identify biomarker positive 
subgroup, strong link 
biomarker and treatment 
needed 
CALGB-10603, 
Lung MATRIX (13-15, 38) 
Hybrid/Mixture Figure 2b 
Specimens and follow up 
information collected all 
patients for future testing  
Large population needs to be 
screened, strong link 
biomarker and treatment 
needed 
TAILORx, 
MINDACT (16, 39) 
Unselected/All comers Figure 2c 
Recruitment not dependent on 
previous testing or biomarker 
status 
Cost may be high if high 
proportion of patients not able 
to contribute biomarker 
measurements, dilution 
treatment effect if only small 
subgroup benefits from 
treatment, use of testing 
methods may be difficult if 
ability to provide adequate 
biological specimen is not an 
eligibility criterion to 
participate in the trial 
EGFR as a Marker 
for Erlotinib in 
Lung Cancer (4, 16) 
Marker Strategy Design 
without randomisation in 
non-marker directed arm Figure 2d 
Recruitment not dependent on 
biomarker status, Cost-
effective as biomarker is only 
assessed in the biomarker 
directed arm, Ethical, Use 
with multiple markers and 
multiple treatments 
Loss of power due to overlap 
in patients, dilution between 
arm difference with overlap in 
patients 
Tumor 
Chemosensitivity 
Assay Ovarian 
Cancer Study (14, 16) 
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Modified Marker Strategy 
Design with 
randomisation in non-
marker directed arm Figure 2e 
Recruitment not dependent on 
biomarker status, Cost –
effective as biomarker is only 
assessed in the biomarker 
directed arm, Ethical, Use 
with multiple markers and 
multiple treatments 
More costly than marker 
strategy design without 
randomisation, Potential 
dilution of the between-arm 
treatment difference  SHIVA (4, 14) 
Interaction/Biomarker 
stratified  Figure 2f 
Allows prognostic value 
marker to be evaluated, gold 
standard for whether treatment 
is dependent on biomarker 
status 
Costly, Cannot be used for 
multiple markers and 
treatments, Can be inefficient 
as needs to be powered to 
detect either a difference in 
effect of treatment in 
biomarker-positive and-
negative patients or effect in 
all patients, Need large sample 
size for testing treatment 
effect separately in two 
marker subgroups MARVEL (14) 
Randomised phase II trial 
design whose outcome 
could help investigators 
decide  on a future phase 
III study design 
In step 1, the null hypothesis is tested 
in the biomarker positive subgroup. 
Based on the results of step 1, step 2 
will either test the null hypothesis in all 
randomly assigned patients or will test 
it in the biomarker negative subgroup. 
Based on the results of steps 1) and 2), 
the investigators will either decide to 
stop testing a particular intervention, or 
to use a biomarker enrichment, 
biomarker stratified or standard phase 
III design for a future phase III trial 
Allows streamlining from 
phase II to III of drug 
development and can be 
incorporated into a phase II/III 
design strategy 
Needs established and 
validated biomarker N/A (18) 
Biomarker informed two-
stage winner  
After interim analysis, less promising 
arms of several treatment arms 
dropped, based on biomarker status, 
with only most promising arm 
continuing on to end of  study 
Assigns more patients to most 
promising treatment 
Needs established and 
validated biomarker N/A (40) 
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Tandem two-step phase II 
trial design incorporating 
a prespecified 
pharmacogenomic 
predictor of response 
All comers stage 1, if number of 
objective responses not high enough in 
all patients, pharmacogenomic 
predictor predicts patients likely to be 
responders and study continues accrual 
only in subgroup for stage 2 
Recruitment not dependent on 
biomarker status until second 
stage 
Needs established and 
validated biomarker of 
response N/A (41) 
Joint inference on a 
subpopulation of  “super-
responders” 
Joint inference on subpopulation of  
“super-responders”, defined by 
baseline-expressed biomarkers, and full 
study population using two-way 
analysis of variance model 
Study progresses only in 
patients more likely to benefit 
Needs established and 
validated biomarker(s) N/A (42) 
Run in phase III design 
using an intermediate 
measurement as a 
predictive biomarker 
All patients tested after short run in 
period; if not statistically significant 
only marker positive subset tested.  
Dependent on results, all patients or 
only marker positive patients 
randomised to trial.  
Study progresses only in 
patients more likely to benefit 
Need intermediate (post 
treatment) measurement as 
predictive biomarker N/A (5) 
Biomarker informed add-
arm design for unimodal 
response 
Interim decisions based on the 
measurements of a biomarker to 
identify inferior treatments in a multi 
arm study 
Inferior study treatments are 
identified in study population 
Requires strong surrogate 
biomarker for toxicity primary 
endpoint N/A (40) 
Bridging Continual 
Reassessment Method 
(CRM) 
Patients are divided into several 
subgroups with different maximum 
tolerated doses (MTD) to drug based 
on certain biomarkers through  a 
mixture estimator to estimate dose-
toxicity curve 
Allows more appropriate 
MTDs to be employed in 
different subgroups of patients 
Needs established and 
validated biomarker N/A (43) 
Marker-based testing methods 
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Sequential testing 
Study hypothesis first tested in whole 
population using reduced α and if 
significant treatment considered 
effective in all; if not, treatment effect 
evaluated in biomarker defined subset,  
using remaining α.  If evidence 
treatment works best in biomarker 
defined subgroup, testing first done in 
subgroup followed by whole 
population.   
Sequentially controls and 
preserves study-wise type I 
errors 
Needs established and 
validated biomarker, difficult 
determine whether treatment 
beneficial in biomarker 
negative subgroup N/A (16, 19) 
Marker sequential test  
First tests biomarker-positive patients 
at reduced α, followed by biomarker-
negative patients with the remaining α, 
if test significant.  If test not 
significant, then overall population is 
tested with remaining α. 
 Allows overall type-I error 
level to be controlled 
Needs established and 
validated biomarker N/A (19, 20) 
Parallel testing strategy 1 
Separate testing done simultaneously in  
biomarker positive and negative 
subgroups  
Help determine effect in both 
positive and negative 
subgroups 
Requires high sample size as 
necessitates allocating overall 
α between two subgroup tests 
making significance hard to 
achieve N/A (19) 
Parallel testing strategy 2 
Tests both overall and biomarker-
positive populations simultaneously 
with strength of the predictive value of 
biomarker determining whether 
required sample size driven by 
biomarker-positive or whole population 
hypotheses 
Helps determine a more 
appropriate sample size Needs predictive biomarker N/A (19) 
Adaptive design methods 
Covariate-adaptive 
randomization 
 Uses overall covariate distribution 
among treatment groups to determine 
treatment allocation for next enrolling 
patient 
Allows prognostic factors to 
be balanced among treatment 
arms 
Needs very accurate covariate 
information N/A (24) 
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Response-adaptive 
randomization  
Uses previous patient's response to 
treatment in interim data to determine 
next enrolling patient's allocation, so 
that if successful,  next patient will be 
assigned to same treatment; otherwise 
to the alternative treatment, potentially 
incorporating marker status 
Higher probability of 
assigning more patients to 
more efficacious treatment 
Necessitates response to be 
assessed in relatively short 
time period I-SPY2 (24, 27, 44) 
Outcome-based adaptive 
randomization 
Uses outcome data accumulated in trial 
to randomly assign patients to 
treatments based on biomarker status 
Higher probability of 
assigning more patients to 
more efficacious treatment 
Requires short-term reliable 
outcome and may result in 
bias I-SPY2, BATTLE (21, 44, 45) 
Adaptive accrual  
Accrual ensues in both marker-defined 
subgroups until interim analysis where 
if treatment effect in one group does 
not reach futility boundary, accrual 
stopped to subgroup with only other 
subgroup continuing accrual until total 
planned sample size reached 
Allows more appropriate 
patients to be targeted for 
treatment  
Need to ensure subgroups are 
well defined by good 
validated biomarker N/A (16) 
Biomarker-adaptive 
parallel Simon two-stage  
Conducts two parallel studies in 
biomarker negative and positive 
subgroups, design continues enrolling 
unselected patients in stage II if 
number of responses to drug in 
biomarker-negative group in stage I 
meets/exceeds a cut-off.  Otherwise 
only biomarker positive patients 
enrolled 
Allows more appropriate 
patients to be targeted for 
treatment  
Need prospectively defined 
cut-off N/A (29) 
Phase III design for setting 
of a single binary 
biomarker stratification  
Futility monitoring performed in  
biomarker negative patients at interim 
analysis based on joint prior 
distribution for treatment effects in 
both positive and negative subgroups, 
accrual can then be continued or halted 
in subgroup 
Allows more appropriate 
patients to be targeted for 
treatment  
Needs established and 
validated biomarker N/A (15) 
17 
   
 
 
Bayesian adaptive marker-
stratified  
Both response-adaptive randomization 
according to the patients’ biomarker 
profiles as well as an interim analysis 
with early stopping rules are used 
Higher probability of 
assigning more patients to 
more efficacious treatment 
Needs established and 
validated biomarker N/A (27) 
Adaptive enrichment  
All eligible subjects recruited in first 
stage, followed by interim analysis 
where study design may be switched to 
all-comer design or allows termination 
of the biomarker negative cohort 
depending on the interim analysis 
results, in Stage 2  
Allows sample size, end 
points, randomization ratio 
and eligibility criteria to be 
adjusted  
Study population drift, loss of 
study power, loss of integrity 
of original trial, Needs 
established and validated 
biomarker N/A (30, 31) 
Adaptive testing methods 
Adaptive version of the 
testing approaches  
Treatment effects of potential marker-
based subpopulations evaluated 
through utility functions at interim 
analysis for stage two trial testing, 
using a Bayesian approach assuming 
prior distribution on efficacy 
parameters.  Patients first recruited 
from whole population and at interim 
analysis, trial adapted to continue only 
in subpopulation.  
Allows more appropriate 
patients to be targeted for 
treatment  
Prevalence in population 
should be well known, needs 
established and validated 
biomarker N/A (32) 
Bayesian prediction model 
to help predict whether 
biomarker truly associated 
to clinical outcome 
Bayesian meta-analytic method for 
building prediction model between 
biomarker and the clinical endpoint. 
Used to predict rate ratio of clinical 
endpoint from an early biomarker. 
Proposed prediction model evaluated 
using extensive simulations 
Requires only previous trial-
level summary data in model 
building, no patient-level data 
necessary 
Sample size estimation  
involving biomarker may pose 
difficulties,  go/no go decision 
rules based on biomarker need 
to be determined N/A (33) 
Bayesian adaptive design 
for simultaneously testing 
several predictive 
biomarkers and new 
experimental treatments in 
multi-arm phase II trials 
Uses Bayesian adaptive randomisation 
procedure where patients recruited 
before first interim 
analysis are initially randomised 
equally between control and all 
experimental 
treatments linked to their tumour 
biomarkers.  At each interim analysis, 
Time and cost efficient way of 
matching and testing novel 
predictive biomarkers and new 
interventions 
Managing the randomisation 
and changing the allocation 
ratios after an interim analysis 
can be challenging, needs 
established and validated 
biomarkers N/A (34) 
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Bayesian logistic regression model 
fitted to model the probability of 
treatment success. Posterior 
probabilities from the model that each 
experimental treatment is superior to 
the control for each biomarker profile 
can be used to update the allocation 
probabilities to each arm 
Biomarker-adaptive 
threshold  Figure 3a 
Allows for parallel evaluation 
of new intervention in all 
patients at prespecified α, as 
well as 
establishment/validation of 
biomarker cut-off point, if the 
phase 1 analysis is not 
significant, using the 
remaining α Need pre-existing biomarker N/A (35) 
Adaptive signature  Figure 3b 
Allows development and 
testing of a biomarker 
signature based on high-
dimensional data.   
Limited power unless K-fold 
cross-validation procedure 
used N/A (36, 37) 
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4.3. Other emerging design methods: 
Some methods of incorporating biomarkers into clinical trials do not easily fit into the 
marker-based/adaptive methods classification. One of these is the Longitudinal Cohort Study 
With or Without Nested Clinical Trials (46), where tumour profiling of patients in an 
accredited diagnostic laboratory allows an individual centre to participate and enrol patients 
in multiple nested clinical trials.  The Histology-Based Clinical Trial Design, also called an 
umbrella or platform trial (46), allows a number of agents to be matched to specific molecular 
characteristics in one tumour type using a prespecified set of rules in a standing trial structure 
(15).  The effectiveness of treatment assignments based on molecular profiling results are 
then compared to a control arm (2).  A key advantage is that the design, conduct, and analysis 
of each sub-study are independent of the other sub-studies; however this model requires a 
large sample size and it is resource intensive (2).  This method is used by the LUNG-MAP 
(47),  BATTLE (45), Lung MATRIX (38) and FOCUS4 (48) studies, among others.  An 
alternative to the umbrella trial is the Histology-Independent, Aberration-Specific Clinical 
Trial Design, otherwise known as a bucket or basket trial (46) which is designed to discover 
the effects of a targeted agent against a specific molecular characteristic across different 
tumour types.  The key disadvantages of this model are the potential of false negative 
conclusions if the trial has insufficient representation of patients with tumour types having 
the molecular characteristic of interest, and that it evaluates only one drug-molecular 
characteristic pair at a time (2).  The NCI MATCH trial uses this method (49).   
 
5.0 DISCUSSION: 
Incorporation of a biomarker into the design of clinical trial poses numerous challenges 
including that it must statistically be based on the prevalence and distribution of the marker in 
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the patient population and the chosen clinical endpoint so that the required sample size to test 
the hypothesis can be estimated (50); as well as estimating the unavailability rate of 
biomarker measurements within those calculations (14).  Furthermore, the optimal patient 
population for the study needs to be considered, as well as whether the strength of the marker 
effect is sufficient to separate patients into meaningful outcome groups without overlap (50).   
Regulatory agencies now require that biomarker cut-off points splitting patients into high and 
low risk groups be defined and validated for use in patient populations (51).  Splitting a 
continuous measure into a dichotomous group reduces the power to detect a real association 
with outcome, but if optimized cut-off values are used, then they should be determined using 
a training data set with an independent testing data set to validate the cut-off point (51).  
Using a cut-off point as reported from another study or defined based on the distribution of 
marker level among patients without use of clinical outcome data is also unbiased (51).  
Clinically the biomarker needs to be considered in terms of the toxicity of the proposed 
therapy and should be able to be assimilated into routine clinical practice in a cost effective 
way, must possess a highly significant predictive value, and be independent of the known 
clinicopathologic predictors of prognosis (50).  Additionally, it needs to have therapeutic 
implications readily interpretable by a clinician and have been validated in independently 
confirmed phase III studies (51).  Biologically, this requires that the marker can be assessed 
reproducibly in numerous clinical samples by a well-characterized, standardised, accurate and 
quality controlled assay system (50).  For such an assay to be developed, this necessitates that 
the biology of the marker be well understood and that the marker assay results be statistically 
associated to high-quality patient data (51).   To ensure reproducibility, preclinical work 
should include a statement about the test’s quality controls, what the assay is designed to 
measure, optimal assay conditions, the specific kit or critical reagents, details of the scoring 
system, selection of a uniform threshold for binary interpretation of results, a statement 
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regarding the reproducibility or precision, sensitivity, specificity, and a reference to the 
clinical validation of the assay, such as comparing results using the same samples in different 
laboratories (50).  As assays can change due to new platform availability and as new 
promising biomarkers can be discovered during the course of an ongoing trial, a flexible 
protocol should be adopted to incorporate emerging changes along with good specimen 
storage so that biopsies can be re-tested with the new assay and results compared to the old 
assay (52).  Also as bioinformatics software and assay platform regularly change, it is 
important to specify the version used during the course of a clinical trial. 
As tissue biopsies are invasive and tumours have heterogeneity, there is a potentially 
small amount of available tumour specimen and given that not all tumours can be biopsied 
due to poor accessibility, tissue type is another challenge.  The distribution of the marker in 
normal and abnormal tissues (50) needs to be determined in a sufficient numbers of samples.   
Serial biopsies of a patient’s tumour provide a dynamic view of the individual patient’s 
disease course and response to treatment (53); however these are difficult to obtain.  Size of 
the tumour is a potential issue when tissue has been collected retrospectively as larger 
tumours are more likely to end up in frozen tumour banks; allowing generalizability to only 
those. The limited and differential availability of tumour tissue itself may be a function of the 
disease, hospital diagnostic practices, pathology laboratory preservation, storage protocols, 
study population, and has implications for study generalizability and power (54).  
Appropriate, non-invasive and readily accessible tissues, such as liquid biopsy samples 
including circulating blood cells, circulating tumour cells (CTC) or buccal swabs, could serve 
as potential surrogates for tumour tissue (55).  These need to be inexpensive to measure, 
making CTCs problematic due to the small numbers that can be detected with existing 
methods (53).  However CTCs provide an integrated picture of all clones present in the 
patient (53).  Imaging is another attractive alternative as it is noninvasive and therefore better 
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suited to serial measurements (6).  However imaging can be quite costly as it needs to be 
performed on one subject at a time  and requires sophisticated equipment and imaging probes 
(6).  Conversely, imaging offers the ability to assess target expression across all sites of 
disease, to assess sites challenging to biopsy and assay, such as bone, and can act as an early 
response marker as biochemical and molecular changes will likely precede changes in tumour 
size, potentially reducing trial costs by reducing trial duration (6). Adding biomarker to trials 
is very costly in general especially in the case of a low prevalence marker in the population of 
interest (50).   
Ethical concerns are another challenge as knowledge of the biomarker status may affect 
compliance to the randomized treatment and the biomarker status may still correlate with 
clinical features of the patient that might influence treatment preference, even if the 
biomarker status is withheld (14).  Reliable conclusions about a biomarker are more likely to 
arise from large, collaborative (including both research organisations and pharmaceutical 
companies), phase III studies as opposed to many undersized studies using a variety of 
statistical methodology and clinical inclusion criteria (51).  The European Organisation for 
Research and Treatment of Cancer and the National Clinical Trials Network are paving the 
way through the creation collaborative groups to conduct large-scale studies (46, 49).  
Only a few biomarkers have been validated sufficiently to be in clinical use including 
KRAS (56), estrogen and progesterone receptors, c-erbB-2/HER-2/NEU (57), CA-125, 
prostate specific antigen, and human chorionic gonadotropin (55).  Robust preclinical studies 
should first be performed focusing on reliably identifying the drug target as well as 
developing a validated assay for the biomarker (1). The biomarker should then be added to 
phase I trials to better characterise both its assay and its performance, followed by its 
incorporation in phase II trials for hypothesis testing and finally, its inclusion in a phase III 
trial for proper clinical validation (1).  It is critical that proper preclinical work and stringent 
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validation be done before taking forward only the most promising biomarkers into 
confirmatory studies.  Limitations of this review include the exclusion of Non-English papers 
and of those papers with no abstract available.   
 
6.0 CONCLUSIONS: 
Although the incorporation of biomarkers into clinical trials poses numerous 
challenges, lifesaving treatments can be better targeted to appropriate patients so their 
inclusion is of paramount importance.  The future of biomarkers in clinical trials is bright as 
novel designs can help greatly to simplify their incorporation.  The marker-based designs 
described above are already in common usage; however designs such as the biomarker-
adaptive threshold design and the adaptive signature design can help to greatly mitigate many 
of the aforementioned challenges and should be in greater use.  Further approaches are 
needed to answer methodological issues that have not been addressed within the methods 
presented here. 
 
7.0 REFERENCES: 
1. McShane LM, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into phase II 
trials. Clinical cancer research : an official journal of the American Association for Cancer Research. 
2009;15:1898-905. 
2. Kummar S, Williams PM, Lih CJ, Polley EC, Chen AP, Rubinstein LV, et al. Application of 
molecular profiling in clinical trials for advanced metastatic cancers. Journal of the National Cancer 
Institute. 2015;107. 
3. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: 
theoretical considerations and practical challenges. Journal of clinical oncology : official journal of 
the American Society of Clinical Oncology. 2009;27:4027-34. 
4. Mandrekar SJ, An MW, Sargent DJ. A review of phase II trial designs for initial marker 
validation. Contemporary clinical trials. 2013;36:597-604. 
5. Hong F, Simon R. Run-in phase III trial design with pharmacodynamics predictive biomarkers. 
Journal of the National Cancer Institute. 2013;105:1628-33. 
6. Mankoff DA, Farwell MD, Clark AS, Pryma DA. How Imaging Can Impact Clinical Trial Design: 
Molecular Imaging as a Biomarker for Targeted Cancer Therapy. Cancer journal (Sudbury, Mass). 
2015;21:218-24. 
24 
   
 
 
7. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting 
recommendations for tumor MARKer prognostic studies (REMARK). Nature clinical practice Urology. 
2005;2:416-22. 
8. McGuire WL. Breast cancer prognostic factors: evaluation guidelines. Journal of the National 
Cancer Institute. 1991;83:154-5. 
9. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of 
epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic 
colorectal cancer patients treated with cetuximab. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. 2007;25:3230-7. 
10. Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in 
breast cancer. Breast cancer research and treatment. 1998;52:289-303. 
11. Polley MY, Freidlin B, Korn EL, Conley BA, Abrams JS, McShane LM. Statistical and practical 
considerations for clinical evaluation of predictive biomarkers. Journal of the National Cancer 
Institute. 2013;105:1677-83. 
12. Hayes DF, Bast RC, Desch CE, Fritsche H, Jr., Kemeny NE, Jessup JM, et al. Tumor marker 
utility grading system: a framework to evaluate clinical utility of tumor markers. Journal of the 
National Cancer Institute. 1996;88:1456-66. 
13. Rothmann MD, Zhang JJ, Lu L, Fleming TR. Testing in a Prespecified Subgroup and the Intent-
to-Treat Population. Drug information journal. 2012;46:175-9. 
14. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. 
Journal of the National Cancer Institute. 2010;102:152-60. 
15. Simon R. Biomarker based clinical trial design. Chinese clinical oncology. 2014;3:39. 
16. Lin JA, He P. Reinventing clinical trials: a review of innovative biomarker trial designs in 
cancer therapies. British medical bulletin. 2015;114:17-27. 
17. Liu A, Liu C, Li Q, Yu KF, Yuan VW. A threshold sample-enrichment approach in a clinical trial 
with heterogeneous subpopulations. Clinical trials (London, England). 2010;7:537-45. 
18. Freidlin B, McShane LM, Polley MY, Korn EL. Randomized phase II trial designs with 
biomarkers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 
2012;30:3304-9. 
19. Freidlin B, Sun Z, Gray R, Korn EL. Phase III clinical trials that integrate treatment and 
biomarker evaluation. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology. 2013;31:3158-61. 
20. Freidlin B, Korn EL, Gray R. Marker Sequential Test (MaST) design. Clinical trials (London, 
England). 2014;11:19-27. 
21. Freidlin B, Korn EL. Biomarker-adaptive clinical trial designs. Pharmacogenomics. 
2010;11:1679-82. 
22. Time to adapt. Nature. 2010;464:1245-6. 
23. Brannath W, Zuber E, Branson M, Bretz F, Gallo P, Posch M, et al. Confirmatory adaptive 
designs with Bayesian decision tools for a targeted therapy in oncology. Statistics in medicine. 
2009;28:1445-63. 
24. Zang Y, Lee JJ. Adaptive clinical trial designs in oncology. Chinese clinical oncology. 
2014;3:49. 
25. Antoniou M, Jorgensen AL, Kolamunnage-Dona R. Biomarker-Guided Adaptive Trial Designs 
in Phase II and Phase III: A Methodological Review. PloS one. 2016;11:e0149803. 
26. Huang X, Ning J, Li Y, Estey E, Issa JP, Berry DA. Using short-term response information to 
facilitate adaptive randomization for survival clinical trials. Statistics in medicine. 2009;28:1680-9. 
27. Lee JJ, Xuemin G, Suyu L. Bayesian adaptive randomization designs for targeted agent 
development. Clinical trials (London, England). 2010;7:584-96. 
28. Korn EL, Freidlin B. Outcome--adaptive randomization: is it useful? Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology. 2011;29:771-6. 
25 
   
 
 
29. Jones CL, Holmgren E. An adaptive Simon Two-Stage Design for Phase 2 studies of targeted 
therapies. Contemporary clinical trials. 2007;28:654-61. 
30. Simon N, Simon R. Adaptive enrichment designs for clinical trials. Biostatistics (Oxford, 
England). 2013;14:613-25. 
31. Wang SJ, O'Neill RT, Hung HM. Approaches to evaluation of treatment effect in randomized 
clinical trials with genomic subset. Pharmaceutical statistics. 2007;6:227-44. 
32. Graf AC, Posch M, Koenig F. Adaptive designs for subpopulation analysis optimizing utility 
functions. Biometrical journal Biometrische Zeitschrift. 2015;57:76-89. 
33. Jiang Z, Song Y, Shou Q, Xia J, Wang W. A Bayesian prediction model between a biomarker 
and the clinical endpoint for dichotomous variables. Trials. 2014;15:500. 
34. Wason JM, Abraham JE, Baird RD, Gournaris I, Vallier AL, Brenton JD, et al. A Bayesian 
adaptive design for biomarker trials with linked treatments. British journal of cancer. 2015;113:699-
705. 
35. Jiang W, Freidlin B, Simon R. Biomarker-adaptive threshold design: a procedure for 
evaluating treatment with possible biomarker-defined subset effect. Journal of the National Cancer 
Institute. 2007;99:1036-43. 
36. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating 
and prospectively testing a gene expression signature for sensitive patients. Clinical cancer research : 
an official journal of the American Association for Cancer Research. 2005;11:7872-8. 
37. Freidlin B, Jiang W, Simon R. The cross-validated adaptive signature design. Clinical cancer 
research : an official journal of the American Association for Cancer Research. 2010;16:691-8. 
38. Middleton G, Crack LR, Popat S, Swanton C, Hollingsworth SJ, Buller R, et al. The National 
Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. 
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 
2015;26:2464-9. 
39. Viale G, Slaets L, Bogaerts J, Rutgers E, van't Veer L, Piccart-Gebhart MJ, et al. High 
concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) 
of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. Annals of oncology : 
official journal of the European Society for Medical Oncology / ESMO. 2014;25:816-23. 
40. Wang J, Chang M, Menon S. Biomarker Informed Add-arm Design for Unimodal Response. 
Journal of biopharmaceutical statistics. 2015. 
41. Pusztai L, Anderson K, Hess KR. Pharmacogenomic predictor discovery in phase II clinical 
trials for breast cancer. Clinical cancer research : an official journal of the American Association for 
Cancer Research. 2007;13:6080-6. 
42. Glimm E, Di Scala L. An approach to confirmatory testing of subpopulations in clinical trials. 
Biometrical journal Biometrische Zeitschrift. 2015;57:897-913. 
43. Liu S, Pan H, Xia J, Huang Q, Yuan Y. Bridging continual reassessment method for phase I 
clinical trials in different ethnic populations. Statistics in medicine. 2015;34:1681-94. 
44. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive 
breast cancer trial design in the setting of neoadjuvant chemotherapy. Clinical pharmacology and 
therapeutics. 2009;86:97-100. 
45. Kim ES, Herbst RS, Wistuba, II, Lee JJ, Blumenschein GR, Jr., Tsao A, et al. The BATTLE trial: 
personalizing therapy for lung cancer. Cancer discovery. 2011;1:44-53. 
46. Lacombe D, Tejpar S, Salgado R, Cardoso F, Golfinopoulos V, Aust D, et al. European 
perspective for effective cancer drug development. Nature reviews Clinical oncology. 2014;11:492-8. 
47. Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman MW, Hirsch FR, Mack PC, et al. 
Innovative Clinical Trials: The LUNG-MAP Study. Clinical pharmacology and therapeutics. 
2015;97:488-91. 
48. Kaplan R, Maughan T, Crook A, Fisher D, Wilson R, Brown L, et al. Evaluating many 
treatments and biomarkers in oncology: a new design. Journal of clinical oncology : official journal of 
the American Society of Clinical Oncology. 2013;31:4562-8. 
26 
   
 
 
49. Abrams J, Conley B, Mooney M, Zwiebel J, Chen A, Welch JJ, et al. National Cancer Institute's 
Precision Medicine Initiatives for the new National Clinical Trials Network. American Society of 
Clinical Oncology educational book / ASCO American Society of Clinical Oncology Meeting. 2014:71-
6. 
50. Hammond ME, Taube SE. Issues and barriers to development of clinically useful tumor 
markers: a development pathway proposal. Seminars in oncology. 2002;29:213-21. 
51. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. British 
journal of cancer. 1994;69:979-85. 
52. Biankin AV, Piantadosi S, Hollingsworth SJ. Patient-centric trials for therapeutic development 
in precision oncology. Nature. 2015;526:361-70. 
53. D'Arcangelo M, Margetts J, Greystoke A. The use of circulating biomarkers in early clinical 
trials in patients with cancer. Biomarkers in medicine. 2015;9:1011-23. 
54. Hoppin JA, Tolbert PE, Taylor JA, Schroeder JC, Holly EA. Potential for selection bias with 
tumor tissue retrieval in molecular epidemiology studies. Annals of epidemiology. 2002;12:1-6. 
55. Schilsky RL, Taube SE. Tumor markers as clinical cancer tests--are we there yet? Seminars in 
oncology. 2002;29:211-2. 
56. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is 
required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology. 2008;26:1626-34. 
57. Bast RC, Jr., Ravdin P, Hayes DF, Bates S, Fritsche H, Jr., Jessup JM, et al. 2000 update of 
recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice 
guidelines of the American Society of Clinical Oncology. Journal of clinical oncology : official journal 
of the American Society of Clinical Oncology. 2001;19:1865-78. 
8.0 FIGURE LEGENDS: 
Figure 1. Diagram 
Figure 2. Common biomarker-based designs: a. Enrichment design b. Hybrid/Mixture design 
c. Unselected/All comers design d. Marker-based strategy with standard control e. Marker-
based strategy with randomized control f. Interaction/Biomarker stratified design. 
Abbreviations: B=Biomarker, R=Randomize, P=Placebo/control/standard of care arm, 
I=Intervention/experimental arm. 
Figure 3. Common Adaptive designs: a. Adaptive threshold design b. Adaptive signature 
design.  Abbreviations: B=Biomarker, R=Randomize, P=Placebo/control/standard of care 
arm, I=Intervention/experimental arm, C=Compare. 
 
